Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

BACKGROUND: Treatment with direct-acting antiviral agents (DAAs) offers an opportunity to eliminate hepatitis C virus (HCV) endemic among people who inject drugs (PWID) and people enrolled in opioid agonist therapy (OAT) programs. The objective of this study was to estimate and to compare HCV treatm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Subst Abuse Treat Prev Policy
Autors principals: Aas, Christer F., Vold, Jørn Henrik, Skurtveit, Svetlana, Odsbu, Ingvild, Chalabianloo, Fatemeh, Lim, Aaron G., Johansson, Kjell Arne, Fadnes, Lars Thore
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325258/
https://ncbi.nlm.nih.gov/pubmed/32605625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13011-020-00286-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars